Corvus Total Stockholder Equity from 2010 to 2025
| CRVS Stock | USD 8.81 0.37 4.38% |
Total Stockholder Equity | First Reported 2014-12-31 | Previous Quarter 80.2 M | Current Value 71.8 M | Quarterly Volatility 43.8 M |
Check Corvus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Corvus Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 80.8 K, Interest Expense of 968.3 K or Selling General Administrative of 8.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 10.52. Corvus financial statements analysis is a perfect complement when working with Corvus Pharmaceuticals Valuation or Volatility modules.
Corvus | Total Stockholder Equity | Build AI portfolio with Corvus Stock |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Corvus Stock Analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.